ArticleMolecular medicine (Cambridge, Mass.)2026
Fluoxetine suppresses triple-negative breast cancer progression by inducing apoptosis, inhibiting Src-mediated invasiveness, and enhancing anti-tumor immunity.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
background and purposeTriple-negative breast cancer (TNBC) is an aggressive subtype lacking ER, PR, and HER2 expression, with limited treatment options and poor prognosis. Recent evidence suggests the antidepressant fluoxetine may possess antitumor activity. This study evaluated the therapeutic potential and mechanisms of fluoxetine in TNBC.
methodsMDA-MB-231 human and 4T1 murine TNBC cell lines were treated with fluoxetine. Cell viability, apoptosis, migration, invasion, and molecular pathway changes were assessed in vitro. A 4T1 orthotopic mouse model was used to evaluate in vivo antitumor efficacy, toxicity, and immune modulation.
resultsFluoxetine reduced TNBC cell viability in a dose- and time-dependent manner, induced apoptosis via extrinsic (Fas/FasL, caspase-8) and intrinsic (mitochondrial membrane loss, caspase-9) pathways, and activated caspase-3. It inhibited migration and invasion by downregulating VEGF-A, MMP-2, MMP-9, and Cyclin D1, and suppressed the Src/JAK/NF-κB signaling axis and epithelial–mesenchymal transition markers. In vivo, fluoxetine significantly reduced tumor growth without systemic toxicity, enhanced cleaved caspase-3/8/9 expression, suppressed Src/JAK/NF-κB signaling, and increased cytotoxic T lymphocyte activity while reducing tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells. CONCLUSIONS AND IMPLICATIONS: Fluoxetine exerts potent antitumor effects against TNBC by inducing apoptosis, inhibiting metastatic signaling, and enhancing antitumor immunity. These findings support its potential as an adjunctive agent for use in parallel with existing TNBC therapies and warrant further clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.